9 results about "Galactosidase activity" patented technology

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

This invention discloses a method, system, device, medium, and application for constructing a diagnostic model for male infertility, belonging to the fields of male infertility diagnosis, drug screening, and assisted reproductive technology. In this invention, by simultaneously and quantitatively analyzing the pH value, mitochondrial G-quadruplex structure level, and β-galactosidase activity within a single sperm cell, and integrating routine clinical sperm testing parameters and age, a high-precision diagnostic model for male infertility and a drug screening system are established, providing a reference for assisted reproduction to meet practical needs.

This invention relates to the field of anti-aging drug technology, specifically to the application of small molecule compounds in the preparation of anti-aging drugs. These small molecule compounds competitively block the interaction between KDM6A and the vacuolar ATPase V0 domain subunit ATP6V0C by targeting a specific small molecule binding pocket of the histone demethylase KDM6A, thereby inhibiting the demethylation activity of KDM6A on lysine residue 36 of ATP6V0C. These small molecule compounds can effectively downregulate aging-related β-galactosidase activity, improve cell cycle arrest, and reverse the senescent phenotype of nerve cells induced by the environmental pollutant GenX, making them particularly suitable for combating premature aging of nerve cells induced by perfluorinated and polyfluoroalkyl compounds such as GenX. This technical solution can solve the technical problem of the lack of drugs with clearly defined components, a clear mechanism of action, stable efficacy, and the ability to specifically alleviate aging in existing technologies, and has ideal prospects for widespread application.

This invention discloses a collagen tripeptide composition, its preparation method, and its application, belonging to the field of food technology. The collagen tripeptide composition comprises the following raw materials in parts by weight: 80-200 parts of ray collagen peptide, 70-120 parts of collagen tripeptide, 100-300 parts of French flower and fruit powder, 300-600 parts of prickly pear powder, 300-500 parts of sage extract, 100-150 parts of tremella polysaccharide, 300-500 parts of wolfberry powder, and 100-300 parts of astragalus powder. The collagen tripeptide composition of this invention can reduce β-galactosidase activity, exhibiting a good anti-aging effect. Applying the collagen tripeptide composition of this invention can quickly replenish collagen and maintain skin elasticity.

This invention relates to a disaccharide exoglycosidase β-agarase with both galactosidase and β-galactosidase activities and its applications, belonging to the field of biotechnology. This invention discloses for the first time a method for developing a β-agarase from *Pseudomonas alterniflora* (…). Pseudoalteromonas An enzyme, ORF0276, and its encoding gene, possessing both galactosidase and disaccharide exonuclease activities, were obtained from the genome of strain Q02 (sp.). This enzyme exhibits strong thermostability, high pH tolerance, and stable physicochemical properties, thus possessing potential for industrial applications. When degrading agar polysaccharide substrates, it can act on the β-1,4 glycosidic bonds of the sugar chains to produce a product primarily composed of neo-agarbiose, which can be used for the industrial preparation of neo-agarbiose (NA2). This research provides a molecular template and theoretical reference for the discovery of such multi-functional tool enzymes.

This invention relates to an asparagine peptide mixture, its preparation method, and its application in the preparation of products that delay skin aging, belonging to the field of cosmetic technology. The asparagine peptide mixture provided by this invention is an active peptide mixture with a molecular weight <5 kDa, prepared from asparagus root tubers via enzymatic hydrolysis. This asparagine peptide mixture can significantly enhance the vitality of human skin fibroblasts (HSF), promote cell proliferation, and enhance the tissue repair capacity of HSF cells; it can effectively inhibit β-galactosidase activity while increasing the expression level of pre-type I collagen. Furthermore, this invention identifies the top ten most active short peptides in the asparagine peptide mixture through structural identification and activity screening, and demonstrates through molecular docking that the asparagine peptide mixture intervenes in the skin aging process through multiple pathways, providing solid in vitro scientific evidence for the development of natural peptide cosmetics with multiple anti-aging effects from the traditional medicinal plant asparagus.

This invention relates to the field of biotechnology, specifically to a high-yield α-galactosidase-producing mutant strain of *Weizmannii coagulans* and its application. This invention is the first to propose using *Weizmannii coagulans* as an α-galactosidase-producing bacterium. Through mutagenesis, a high-yield α-galactosidase-producing mutant strain was obtained. The fermentation broth of the mutant strain showed a 4.37-fold increase in α-galactosidase activity compared to the original strain, maintaining over 60% activity within a pH range of 6.0–10.0, and exhibiting 1.80 times better heat resistance than the original enzyme. Furthermore, it can hydrolyze the anti-nutritional factors mesenteryne, raffinose, and stachyose in soybean meal, demonstrating high industrial value in the fermented soybean meal and feed processing industries. This invention lays the foundation for the application of *Weizmannii coagulans* in the manufacturing and processing of α-galactosidase.

This invention discloses a method and its application for delaying cellular senescence in the in vitro expansion of mesenchymal stem cells. The method includes delaying the replicative senescence of human mesenchymal stem cells by inhibiting N-cadherin-mediated cell adhesion during in vitro expansion. Inhibition of N-cadherin-mediated cell adhesion includes adding inhibitors or reducing the expression level of genes encoding N-cadherin. The method of this invention can effectively reduce cell adhesion, restore the collective migration ability and traction of cells, and significantly downregulate the expression of aging-related markers p53 and p21, as well as SA-β-galactosidase activity. The method of this invention is simple to operate, low in cost, and can effectively improve the quality and yield of stem cell expansion.